Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:MEGACE

 

 

ONCOLOGIC PROTOCOL

MEGACE

MAJOR INDICATIONS: HORMONAL TREATMENTS FOR BREAST CANCER (ALL STAGES)
IDENTIFICATION: Megace
This drug has been approved by the FDA (Food and Drug Administration) for the treatment of metastatic (Stage IV) breast cancer.
Dose: 40 mg (1 tablet) four times per day.
Route: Given orally
Duration and timing: In the treatment of stage IV disease treatment is continued until disease progression.
Possible Side effects:
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications), appetite stimulation, weight gain.
  • Systemic: fluid retention, edema, tumor flare, hypercalcemia (high calcium levels), hyperglycemia (high glucose levels) and resistance to insulin has been seen.
  • Fertility: adverse effect on fertility is known; this drug should not be taken by women who are pregnant or breast feeding.
  • Respiratory: instances of pulmonary embolism have occurred (blood clot going to the lung), dyspnea (feeling of shortness of breath).
  • Gynecologic: episodes of vaginal discharge and breakthrough bleeding have been noted.
  • Hepatic: elevated liver enzymes.
  • Cardiovascular: hypertension.
  • Integmentary: hair loss.
  • Other: increased risk of developing blood clots.

Back gif

 

1997 - TransMed Network